This month the Antibody Update showcases caffeine as a potential anti-inflammatory agent, how mTOR is related to granuloma formation, and a retinal transplant using induced pluripotent stem cells. Learn more here!
This month's Antibody Update includes news on how your skin bacteria regulate levels of Staphylococus aureus, a new study using single cell sequence analysis to create 3D models of tumor tissue, and development of chimeric antigen receptor T-cells using CRISPR/Cas9 to enhance immunotherapy.
Immune system checkpoint inhibition may not always be the perfecct way to target cancer. Why is it that some patients do not respond positively to certain immunotherapy treatments like Ipilimumab? This blog takes into account the immune system's convoluted nature to understand how immune checkpoint antibodies may not be the problem, and how personalized medicine could help.
The start of the new year has brought some interesting new stories in science and science policy. This Antibody Update looks at The Reproducibility Project's efforts in cancer drug research, changes to encourage vaccine development against less known, but still threatening viruses, and a new study on the mechanism of how macrophages cross the vascular endothelium.
Cancer immunotherapy involves targeting receptors and ligands of T-cells and tumor cells to amplify an immune response. By targeting these receptors and ligands, T-cell anti-cancer activity can be regulated. This blog explains how the receptors CD28 and CTLA-4 and their ligands CD80 and CD86 are involved in T-cell activation and inhibition. Take a look!
ProSci's last Antibody Update of 2016 includes the super effective Ebola vaccine developed by Merck, using the common diabetes drug metformin and the antihypertensive syrosingopine to combat cancer, and a link to a highlight review of the immune checkpoint TIGIT. Check it out!
This months Antibody Update features the first use of CRISPR-Cas9 modified cells being used as therapeutics, the launch of the first vaccine against malaria, and the 21st Century Cures act, which may vastly increase funding of public health agencies for the next decade. Learn more here.
This blog focuses on the differences between bacterial and mammalian cell expression systems. E. coli make excellent organisms for expression of several types of proteins, but do have limitations based on their cellular hardware. This is where mammalian cells can really shine, creating more native, natural proteins and effective antibodies. Learn more here!
The October 2016 Antibody Update includes news on a successful combination immunotherapy for cancer, the story of the Yoshinori Ohsumi's Nobel Prize in Medicine, the release of bacterially infected mosquitoes in Brazil to combat the spread of Zika virus, and a reminder to come looking for ProSci at SfN 2016. Get a look at the October's big news round-up here!
This Antibody Basics looks into the development of recombinant antibodies and their advantages over monoclonal and polyclonal antibodies. Learn about how recombinant antibodies can be developed through display systems, B-cell cloning, or directly from hybridoma.